Notice Number: NOT-AG-21-036
Deadline: November 13, 2024
Objective
The goal of this NOSI is to encourage the development of novel approaches to characterizing, diagnosing, and predicting outcomes in AD and ADRD. Examples of research that might be supported include, but are not limited to, the following:
- Studies that improve antemortem characterization of dementia, particularly ADRDs
- Studies that develop antemortem biomarkers to identify non-AD proteinopathies: a-synuclein (Lewy Bodies), FTD-Tau (4R and 3R), and TDP-43
- Studies that focus on biomarkers that characterize dementia subtypes:
- AD: Posterior cortical atrophy (PCA), hippocampal sparing, dysexecutive, etc.
- LBD: Parkinson’s Dementia, REM sleep disorder, fluctuating levels of consciousness, etc.
- FTD: Pick’s, BvFTD, PSP, CBD, FTD w/ MND, etc.
- Tau vs TDP-43 FTD
- Studies that provide new information about the pathophysiology of AD and/or ADRD
- Biomarkers of inflammation and microglia function altered in AD or ADRD
- Studies that characterize brain networks altered in AD or ADRD
- Studies that identify common neurobiological mechanisms underlying concomitant symptoms and cognitive impairment in AD and ADRD
- Biomarkers of neuropsychiatric symptoms
- Movement disorders: FTD vs LBD vs AD
- Aphasias: logopenic primary progressive aphasia can be AD or FTD
- Studies that aim to identify a surrogate marker for cognition, or a dementia/cognition “stress” test
- Studies that address shortcomings of currently used biomarkers
- Studies further characterizing or understanding biomarkers, already validated or studied in AD or ADRD
For more information, please see the opportunity website.